Publications by authors named "Bruno Michel"

52 Publications

Integrative taxonomy confirms that Gregarina garnhami and G. acridiorum (Apicomplexa, Gregarinidae), parasites of Schistocerca gregaria and Locusta migratoria (Insecta, Orthoptera), are distinct species.

Parasite 2021 23;28:12. Epub 2021 Feb 23.

Molécules de Communication et Adaptation des Microorganismes (MCAM, UMR 7245 CNRS), Département Adaptations du vivant (AVIV), Muséum National d'Histoire Naturelle, CNRS, CP 52, 57 rue Cuvier, 75231 Paris Cedex 05, France.

Orthoptera are infected by about 60 species of gregarines assigned to the genus Gregarina Dufour, 1828. Among these species, Gregarina garnhami Canning, 1956 from Schistocerca gregaria (Forsskål, 1775) was considered by Lipa et al. in 1996 to be synonymous with Gregarina acridiorum (Léger 1893), a parasite of several orthopteran species including Locusta migratoria (Linné, 1758). Here, a morphological study and molecular analyses of the SSU rDNA marker demonstrate that specimens of S. gregaria and specimens of L. migratoria are infected by two distinct Gregarina species, G. garnhami and G. acridiorum, respectively. Validation of the species confirms that molecular analyses provide useful taxonomical information. Phenotypic plasticity was clearly observed in the case of G. garnhami: the morphology of its trophozoites, gamonts and syzygies varied according to the geographical location of S. gregaria and the subspecies infected.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1051/parasite/2021009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901526PMC
March 2021

Enhancing the role played by clinical pharmacists in psychiatric settings to better integrate clinical psychopharmacology into the decision-making process.

Therapie 2021 Mar-Apr;76(2):149-156. Epub 2020 Dec 5.

Pôle de psychiatrie, santé mentale & addictologie des hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1114, 67000 Strasbourg, France; Fédération de médecine translationnelle de Strasbourg, université de Strasbourg, 67000 Strasbourg, France.

The importance of clinical psychopharmacological knowledge for modern psychiatric care is both well-established and underdeveloped. Although psychiatric pharmacists are identified as experts in psychopharmacotherapy based on pharmacists' overall expertise in pharmacotherapy, in real-life health settings, such is not necessarily the case. As a matter of fact, (1) pharmacists' real expertise in pharmacotherapy is mainly seen as useful to patients (as part of therapeutic education), (2) pharmacists' practice methods are usually circumscribed to the framework of quality processes (e.g. comprehensive medication management) which are not particularly useful to clinicians who have a greater need for pharmacotherapeutic skills, (3) the difficulties in terms of collaboration between pharmacists and physicians are well-known. We describe here the implementation of an alternative system of pharmacotherapy counselling inspired by case by cases in which the remote expertise of pharmacists in psychopharmacology guided prescribers towards the implementation of recommendations from the literature. This shared decision-making process integrates both the clinical elements provided by the psychiatrist and the pharmacotherapeutic information provided by the clinical psychopharmacist, to promote evidence-based medicine (algorithmic data in recommendations) and tailor-made solutions (drug-drug and drug-disease interactions) for patients. In our experience, the success of such an initiative is likely to promote the development of clinical psychopharmacology in psychiatric settings. Importantly, within this framework, the pharmacovigilance unit and psychopharmacologist are useful resources to guide the decision-making process of the pharmacist-psychiatrist duo.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.therap.2020.12.011DOI Listing
December 2020

Dendrothripoides moundi (Thysanoptera, Thripidae), a new species from Madagascar.

Zootaxa 2020 Nov 10;4877(2):zootaxa.4877.2.12. Epub 2020 Nov 10.

European Union Reference Laboratory for Insects and Mites 755 Avenue du Campus Agropolis CS 30016, FR-34988 Montferrier-sur-Lez Cedex France..

The genus Dendrothripoides was originally described by Bagnall (1923) from India and is currently represented by five species (ThripsWiki 2020). Dendrothripoides innoxius (Karny) is widely distributed in the Oriental and Pacific regions; D. microchaetus Okajima is from the Philippines and Indonesian archipelago; D. nakaharai Reyes known only from the Philippines, D. poni Kudo from Thailand, and D. venustus Faure from Rhodesia [Zimbabwe] and South Africa (Faure 1941; Kudo 1977; Bournier 2000). Little is known about the biology of these species because collections often have samples with few specimens. D. innoxius is considered a minor pest on Ipomoea crops (Watson Mound 2020) but adults have been taken on the leaves of plants in numerous families (Asteraceae, Convolvulaceae, Dioscoreaceae, Musaceae, Poaceae). Dendrothripoides was classified within the Panchaetothripinae by Priesner (1957) for having a reticulate body surface. However, Ananthakrishnan (1963) indicated that the similarities are superficial, and that this genus should be classified in the Aptinothripina of the Thripinae because the pronotum lacks long setae. The genus is now not included in the Anaphothrips genus-group (Masumoto Okajima 2017), but the systematic position is unclear with a recent morphological phylogenetic analysis indicating a position near the Panchaetothripinae that may be due to superficial resemblance (Zhang et al. 2019).
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.11646/zootaxa.4877.2.12DOI Listing
November 2020

Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.

Eur J Hosp Pharm 2020 Nov 25. Epub 2020 Nov 25.

Service de Pharmacie, Hopitaux universitaires de Strasbourg, Strasbourg, Alsace, France

Objective: The aims of this study were to describe prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis (primary endpoint), then to characterise pharmaceutical interventions (PIs) targeted to these medications and evaluate the impact of these PIs on prescribers' practices (secondary end-points).

Methods: This retrospective observational study was carried out at the University Hospital of Strasbourg (France) from March to April 2020. The analysed population excluded patients from intensive care units but included all other adult patients with COVID-19 who received at least one dose of lopinavir/ritonavir combination, hydroxychloroquine or azithromycin, while inpatients. Analyses were performed by using data extracted from electronic medical records.

Result: During the study period, 278 patients were included. A rapid decrease in lopinavir/ritonavir prescriptions was observed. This was accompanied by an increase in hydroxychloroquine and azithromycin prescriptions until the end of March, followed by a decrease leading to the disappearance of these two medications in April. The pharmaceutical analysis of the prescriptions resulted in 59 PIs of which 21 were associated with lopinavir/ritonavir, 32 with hydroxychloroquine and 6 with azithromycin. Regarding the medication-related problems, the most frequent ones were incorrect treatment durations (n=32 (54.2%)), drug interactions with potential torsadogenic reactions (n=14 (23.7%)) and incorrect dosing (n=6 (10.2%)). From the 59 PIs, 48 (81.4%) were accepted and physicians adjusted the medication regimens in a timely manner.

Conclusion: This study demonstrated the value-even more meaningful in a crisis situation-of a strong synergy between physicians and pharmacists for patient-safety focused practices.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/ejhpharm-2020-002449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689541PMC
November 2020

The genus Holopothrips Hood, 1914 in Guadeloupe with descriptions of two new species (Thysanoptera, Phlaeothripidae).

Zootaxa 2020 Jun 2;4786(2):zootaxa.4786.2.6. Epub 2020 Jun 2.

CIRAD, CBGP (INRAE, IRD, CIRAD, Montpellier SupAgro, Montpellier Univ), 755 av. du Campus Agropolis, CS 30016, 34988 Montferrier-sur-Lez cedex, France..

After the revision of the genus Holopothrips provided by Lindner et al. (2018), the specimens of Holopothrips kept in the CIRAD/CBGP collection collected in Guadeloupe were re-examined. Two species previously identified as Holopothrips tenuis and Holopothrips sp. are described here as H. brevisetus sp. n. and H. guadeloupensis sp. n. Holopothrips ananasi is here removed from the list of species reported to Guadeloupe after re-examination of labelled specimens. Information on all the species of Holopothrips found in Guadeloupe, and an identification key to the species of Holopothrips recorded from the Caribbean are provided.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.11646/zootaxa.4786.2.6DOI Listing
June 2020

Adherence to oral anticancer chemotherapies and estimation of the economic burden associated with unused medicines.

Int J Clin Pharm 2020 Oct 28;42(5):1311-1318. Epub 2020 Aug 28.

Faculty of Pharmacy, University of Strasbourg, Strasbourg, France.

Background The list of oral and expensive chemotherapy agents has lengthened over the last few years and has created unique medication adherence concerns. In a real-life setting, patients often do not take their medications as prescribed. This pattern is associated with poor outcomes and increased health care costs. Objectives To estimate the adherence to oral anticancer chemotherapies and to determine the economic burden of unused medicines due to patients' death. Setting Alsace (France). Method This retrospective study was carried out by using ERASME, an Insurance Healthcare database. Main outcome measures Adherence was calculated using medication possession ratio and economic impact using prescription refill data. Results 10,734 patients were treated with oral anticancer medicines (cytotoxic agents, hormonal and targeted therapies). Averaged adherence of 0.86 was observed although it varied significantly between subclasses (cytotoxic agents: 0.69 ± 0.14, hormonal therapy: 0.91 ± 0.17 and targeted therapy: 0.79 ± 0.17). 1631 patients died during the study period. The expenses related to unused chemotherapies amounted to €152,175. Conclusions Our data showed that overall adherence to oral anticancer medicines was above the acceptable limit of adherence of 80% with a marked graduation in values between cytotoxic agents, hormonal and targeted therapies. These statistical significant differences in medication possession ratio could be related to the intrinsic toxicity of the three subclasses of molecules, their tolerance and adverse effects. To limit the cost associated with unused medicines, interventions such as dispensing expensive oral anticancer chemotherapies per unit over shorter periods and not only on monthly intervals could be implement.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11096-020-01083-4DOI Listing
October 2020

Self-Powered Implantable Medical Devices: Photovoltaic Energy Harvesting Review.

Adv Healthc Mater 2020 09 29;9(17):e2000779. Epub 2020 Jul 29.

James Watts school of Engineering, University of Glasgow, Glasgow, G12 8QQ, UK.

Implantable technologies are becoming more widespread for biomedical applications that include physical identification, health diagnosis, monitoring, recording, and treatment of human physiological traits. However, energy harvesting and power generation beneath the human tissue are still a major challenge. In this regard, self-powered implantable devices that scavenge energy from the human body are attractive for long-term monitoring of human physiological traits. Thanks to advancements in material science and nanotechnology, energy harvesting techniques that rely on piezoelectricity, thermoelectricity, biofuel, and radio frequency power transfer are emerging. However, all these techniques suffer from limitations that include low power output, bulky size, or low efficiency. Photovoltaic (PV) energy conversion is one of the most promising candidates for implantable applications due to their higher-power conversion efficiencies and small footprint. Herein, the latest implantable energy harvesting technologies are surveyed. A comparison between the different state-of-the-art power harvesting methods is also provided. Finally, recommendations are provided regarding the feasibility of PV cells as an in vivo energy harvester, with an emphasis on skin penetration, fabrication, encapsulation, durability, biocompatibility, and power management.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/adhm.202000779DOI Listing
September 2020

[Tinnitus and venlafaxine discontinuation syndrome].

Therapie 2020 Jun 26. Epub 2020 Jun 26.

Pharmacopsy Alsace, service de pharmacie clinique, établissement public de santé Alsace Nord, 67170 Brumath, France. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.therap.2020.06.009DOI Listing
June 2020

A case of paroxetine-induced antidepressant discontinuation syndrome related to pregnancy: time to redefine the syndrome?

Psychiatry Res 2020 09 26;291:113259. Epub 2020 Jun 26.

Service de neurologie, CHRU Nancy, Nancy, France AND Pôle universitaire de psychiatrie du grand Nancy, CPN, Laxou, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psychres.2020.113259DOI Listing
September 2020

Memantine misuse and social networks: A content analysis of Internet self-reports.

Pharmacoepidemiol Drug Saf 2020 09 29;29(9):1189-1193. Epub 2020 Jun 29.

Faculty of Pharmacy, University of Strasbourg, Strasbourg, France.

Purpose: Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist currently used for moderate-to-severe Alzheimer's disease. Although the risk of memantine abuse is very low, other NMDA receptor antagonists, such as phencyclidine and ketamine, are well known to drug users. The purpose of this study was to collect data on social networks in order to identify unexpected forms of memantine abuse.

Method: A Google Trends search was used to highlight reddit.com as a major source of social discussions about memantine. Self-reported users experiences posted on reddit.com were recorded and sorted using representative keywords.

Results: From 2010 to November 2019, 307 topics citing memantine were identified on reddit.com and 136 users experiences extracted from the topics were recorded. The main use identified was "self-medication" based on off-label uses of memantine such as anxiety, depression, attention-deficit hyperactivity disorder, or obsessive-compulsive disorder (n = 87 reports), followed by nootropic (42) and recreational (39) uses. The average reported doses for acute and chronic uses were 156 ± 110 mg and 23 ± 24 mg respectively. For chronic use, the average duration was 15 ± 29 weeks. Most chronic users (77 out of 100) reported at least one side effect.

Conclusion: Memantine misuse seems to be a growing phenomenon. Beyond expected use for recreational purpose; the main uses identified on reddit.com were not reported in the medical literature. Off-label uses and nootropic purposes seemed to be key features of memantine misuse.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.5070DOI Listing
September 2020

COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?

Br J Clin Pharmacol 2020 06 7;86(6):1176-1177. Epub 2020 May 7.

Pôle Hospitalo-Universitaire de Psychiatrie d'Adultes du Grand Nancy, Centre Psychothérapique de Nancy, Laxou, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.14335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256125PMC
June 2020

A new species of the genus Thrips (Thysanoptera, Thripidae) from the Malagasy Region.

Zootaxa 2020 Mar 12;4750(3):zootaxa.4750.3.13. Epub 2020 Mar 12.

European Union Reference Laboratory for Insects and Mites 755 avenue du campus Agropolis CS 30016 FR-34988 Montferrier-sur-Lez Cedex, France..

The genus Thrips comprises 296 species (ThripsWiki 2019) and is the largest of all Terebrantian genera. The only other Thysanopteran genera comparable in size are the phlaeothripids Haplothrips and Liothrips. Species of Thrips can be found in flowers and on leaves of a wide variety of plants from grasses to trees. Most of them are beneficial pollinators (Garcia-Fayos Goldarazena 2008; Eliyahu et al. 2015), while others are pests and cause significant economic damage (Mound Marullo 1996). Some of them are polyphagous and widespread, while others are rarely seen and restricted to one species of plant (Palmer 1992).
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.11646/zootaxa.4750.3.13DOI Listing
March 2020

Anticoagulant and antiplatelet combined therapy in patients 75 years and over with atrial fibrillation: a prospective observational study assessing adherence to clinical guidelines.

Eur J Hosp Pharm 2020 03 28;27(2):84-89. Epub 2018 Aug 28.

Department of Geriatric, University Hospital of Strasbourg, Strasbourg, France.

Objective: According to current guidelines on atrial fibrillation (AF), the addition of an antiplatelet therapy to an anticoagulant for a stable vascular disease does not decrease the ischaemic hazard but increases the risk of bleeding. The aim of the study was to assess compliance of practices with existing clinical guidelines concerning the use of anticoagulant-antiplatelet combined therapy in patients 75 years and over with AF.

Methods: This prospective observational study was carried out at the University Hospital of Strasbourg (France) between August 2016 and January 2017 with data collection on 1 day of every month. To be included, the patient had to be 75 years and over with AF and treated with anticoagulant-antiplatelet therapy. The population included all the patients admitted at the hospital excluding those from the Gynaecology-Obstetrics and Paediatrics departments. With regard to clinical ongoing guidelines (French, European, American and Canadian), the patients were sorted into three groups. Group 1: combined therapy in compliance with recommendations; Group 2: combined therapy debatable as to benefit-risk ratio; and Group 3: combined therapy not compliant with recommendations.

Result: Ninety-three out of 3307 patients 75 years and over received anticoagulant-antiplatelet combined therapy prior to their hospital admission. Thirty-two patients (34.4% - Group 1) had experienced an acute event and/or revascularisation within the past year. Twenty-four patients (25.8% - Group 2) had not experienced recent revascularisation and had stable coronary disease but were suffering from peripheral artery disease. Group 3 consisted of 37 patients , none of which had experienced recent revascularisation or had unstable coronary disease. For all groups, the main dual therapy was acetylsalicylic acid + fluindione (59.1%).

Conclusion: In our study, 37 antiplatelet (39.8%) treatments could have been stopped. These results should spur prescribers into regular reassessment of combination antithrombotic therapy since it contributes to polypharmacy and increases the risk of adverse events.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/ejhpharm-2018-001520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043253PMC
March 2020

An earbud-type wearable (A hearable) with vital parameter sensors for early detection and prevention of heat-stroke.

Annu Int Conf IEEE Eng Med Biol Soc 2019 Jul;2019:7049-7055

Heat-stroke has become a serious problem in Japan, especially for elderly citizens. For the early detection and prevention of heat-stroke, a wearable health monitor for in-ear use is developed which is subsequently called "Hearable". It aims to measure three vital parameters: Core body temperature, sweat rate and sweat or interstitial sodium ion (Na) concentration. The eardrum is a good place to measure the core body temperature, because it is close to the carotid artery and the brain. We develop a hearable prototype and it consists of an audio earbud, a sensor earbud and a micro controller. Concerning the sensor earbud, a present prototype includes an eardrum (tympanic) temperature sensor and a sweat rate sensor and we implement two variants. Variant-1 focuses on the sweat rate sensing using a humidity & temperature sensor located close to the eardrum and Variant-2 focuses on the eardrum temperature sensing using an IR temperature sensor. Concerning the sweat rate sensing, unlike conventional sweat sensors, our prototypes do not include an air flow pump, which is typically used to determine the air flow rate. We demonstrate the accuracy of sweat rate sensing based on the air flow rate measured from the evaporation of defined amount of water. We use Variant-2 to demonstrate the monitoring of the eardrum temperature and the sweat rate to differentiate a calm state and jogging.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1109/EMBC.2019.8856821DOI Listing
July 2019

High-dose quetiapine and therapeutic monitoring.

Eur J Hosp Pharm 2019 Sep 6;26(5):285-287. Epub 2018 Aug 6.

Service de Pharmacie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Quetiapine is an atypical antipsychotic with a good safety profile permitting its administration beyond the maximum dose of 800 mg/day. We report the case of a patient with a resistant schizophrenia treated with high doses of quetiapine (up to 2000 mg/day) combined with drug monitoring and with favourable therapeutic response and tolerance.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/ejhpharm-2018-001605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788267PMC
September 2019

IoT-Based Home Monitoring: Supporting Practitioners' Assessment by Behavioral Analysis.

Sensors (Basel) 2019 Jul 23;19(14). Epub 2019 Jul 23.

Università degli Studi di Parma, Dip. Ingegneria e Architettura, Parco Area delle Scienze 181/A, 43124 Parma (PR), Italy.

This paper introduces technical solutions devised to support the Deployment Site - Regione Emilia Romagna (DS-RER) of the ACTIVAGE project. The ACTIVAGE project aims at promoting IoT (Internet of Things)-based solutions for Active and Healthy ageing. DS-RER focuses on improving continuity of care for older adults (65+) suffering from aftereffects of a stroke event. A Wireless Sensor Kit based on Wi-Fi connectivity was suitably engineered and realized to monitor behavioral aspects, possibly relevant to health and wellbeing assessment. This includes bed/rests patterns, toilet usage, room presence and many others. Besides hardware design and validation, cloud-based analytics services are introduced, suitable for automatic extraction of relevant information (trends and anomalies) from raw sensor data streams. The approach is general and applicable to a wider range of use cases; however, for readability's sake, two simple cases are analyzed, related to bed and toilet usage patterns. In particular, a regression framework is introduced, suitable for detecting trends (long and short-term) and labeling anomalies. A methodology for assessing multi-modal daily behavioral profiles is introduced, based on unsupervised clustering techniques. The proposed framework has been successfully deployed at several real-users' homes, allowing for its functional validation. Clinical effectiveness will be assessed instead through a Randomized Control Trial study, currently being carried out.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/s19143238DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679511PMC
July 2019

Iatrogenic hypoglycemia-related hospital admissions identified through databases: economic burden and causes.

Int J Clin Pharm 2019 Oct 23;41(5):1159-1165. Epub 2019 Jul 23.

Department of Pharmacy, University Hospital of Strasbourg, NHC, Service de Pharmacie, 1, Place de l'Hôpital, 67091, Strasbourg Cedex, France.

Background Hypoglycemia is an acute and frequent complication of diabetes. Objectives To assess the number of hospital admissions due to iatrogenic hypoglycemia in Alsace (France) over a year, to estimate the associated economic burden and to identify causes. Method A retrospective analysis was performed using data extracted from hospital databases. Costs were calculated from French official tariffs. Setting 31 public and private hospitals. A review of the medical records of patients with iatrogenic hypoglycemia-related hospital admissions was performed at the University Hospital of Strasbourg. Main outcome measures Hypoglycemia-related hospital admissions: number, costs and causes. Results Out of 42,381 hospitalizations, 147 iatrogenic hypoglycemia-related hospital admissions (0.4%) were identified; 41 patients with type 1 diabetes mellitus and 106 with type 2. The total cost associated to the 147 events was € 407,441. The median cost per patient was € 1,224.6 [563.0-2,505.7 (interquartile range)] for type 1 diabetes mellitus and € 3,670.9 [2,505.7-3,670.9] for type 2. Forty-six patients over the 147 were coming from the University Hospital of Strasbourg. In this hospital, the most common origin of the hypoglycemia was missed meals (n = 7), the second was a mismatch between antidiabetic medicines and carbohydrate intake (n = 6), the third was an incorrect use of antidiabetic medicines (n = 5). Conclusions 147 hospitalizations due to iatrogenic hypoglycemia were identified with an estimated global cost of € 407,441. Optimizing therapy with low-risk hypoglycemic medicines, improving access to continuous glucose monitoring systems and offering adequate education, could help address the causes of hypoglycemia.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11096-019-00877-5DOI Listing
October 2019

Potential Statin Overuse in Older Patients: A Retrospective Cross-Sectional Study Using French Health Insurance Databases.

Drugs Aging 2019 10;36(10):947-955

OMEDIT Grand Est, Regional Health Agency, Strasbourg, France.

Background: Although compelling evidence exists supporting statins (HMG-CoA reductase inhibitors) for secondary prevention in older patients with clinical atherosclerotic diseases, the same cannot be said for primary prevention.

Objectives: The objectives of this study were to estimate the frequency of potential statin overuse in older patients, the potential drug cost savings if corrected, and the associated factors.

Methods: A retrospective cross-sectional study was conducted in Alsace and Lorraine (France) from 1 January to 30 April 2017. All statin users aged 80 years or over living in the community (including nursing homes) and identified from the French health insurance database were analyzed. Potential statin overuse was defined according to the STOPP/START (Screening Tool of Older People's Prescriptions/Screening Tool to Alert to Right Treatment) criteria.

Results: Among the 38,268 aged insured, 23,228 (60.7%) had potential statin overuse. Of those living in the community, 22,132 (60.0%) patients had potential statin overuse: 12,352 (55.8%) for primary and 9780 (44.2%) for secondary prevention. Among nursing home residents, 1096 (79.0%) had potential statin overuse: 394 (35.9%) for primary and 702 (64.1%) for secondary prevention. The potential drug cost savings associated with the adjustment of potential statin overuse were €924,100 for the study period. Living in nursing home [adjusted odds ratio (OR) 3.91, 95% confidence interval (CI) 2.82-5.41] and being a female (OR 2.84, 95% CI 2.54-3.17) were the main risk factors associated with potential statin overuse.

Conclusion: The frequency of potential statin overuse is very high among older people aged 80 years or over, highlighting the need to re-evaluate statin therapy and consider deprescribing, particularly for primary prevention and in nursing homes.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-019-00695-4DOI Listing
October 2019

High-Power Adsorption Heat Pumps Using Magnetically Aligned Zeolite Structures.

ACS Appl Mater Interfaces 2019 Jul 28;11(27):24037-24046. Epub 2019 Jun 28.

Complex Materials, Department of Materials , ETH Zurich , 8093 Zurich , Switzerland.

Adsorption heat pumps offer a clean, zero-emission technology for universally applicable cooling or heating utilizing water as a refrigerant and waste or renewable heat as driving energy instead of electricity. Despite their attractive environmentally friendly prospects, the broader application of such classes of heat pumps has not yet been possible, mainly because of the low power density of adsorption heat exchangers and the corresponding large size and high cost of the adsorption heat pumps. We report an inexpensive route for the fabrication of zeolite coatings with high adsorption power density based on the bottom-up assembly of colloids directed by magnetic and capillary forces. Such an assembly process relies on the chaining of oil droplets under an external magnetic field during deposition of the coating, followed by the formation of a percolating network of bridged adsorbent particles upon drying. This results in vertically open channels and thermal bridges that facilitate directed mass and heat transport across the structured zeolite coating during sorption cycles. By reaching up to 3.3-fold higher performance than their unstructured counterparts using readily available zeolite as an adsorbent material, the architectured coatings produced through this facile, upscalable approach hold great potential for next-generation adsorption heat pumps.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.9b04692DOI Listing
July 2019

Revision of the genus Disparomitus van der Weele, 1909 with descriptions of four new species (Neuroptera, Ascalaphidae).

Authors:
Bruno Michel

Zootaxa 2019 Jan 29;4551(1):1-39. Epub 2019 Jan 29.

CBGP, CIRAD, Montpellier SupAgro, INRA, IRD, Univ Montpellier, Montpellier, France CIRAD, CBGP, Montpellier, France..

The genus Disparomitus van der Weele is revised and redescribed. Thirteen species are recorded: Disparomitus abyssinicus van der Weele, D. bacillus (Gerstaecker), D. brevistigma (Esben-Petersen), D. caviceps n. sp., D. citernii Navás, D. haullevillei (Navás) n. comb., D. kimminsi n. sp., D. lineatus n. sp., D. sellatus (Navás) n. comb., D. simplex Kimmins, D. spatula n. sp., D. transvaliensis (van der Weele) and D. yemenicus Hölzel. Disparomitus horvathi van der Weele and D. schoutedeni Navás are considered nomina dubia. The genera Nanomitus Navás and Nagacta Navás are synonymnized with Disparomitus. Nagacta leplaei Navás, N. schoutedeni Navás, Suphalacsa microstigma Navás and Disparomitus schultzei Esben-Petersen are considered as junior synonyms of D. haullevillei. D. longus Navás is considered a junior synonym of D. transvaliensis. Suphalasca subcostalis Navás is considered a junior synonym of D. bacillus. Disparomitus rufocostatus Esben-Petersen, D. maynei Navás and D. congoensis Navás are removed from the genus Disparomitus. All species placed in Disparomitus are illustrated. The distribution of the taxa as well as ecological and behavioral information are provided.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.11646/zootaxa.4551.1.1DOI Listing
January 2019

Benzodiazepines Withdrawal: Initial Outcomes and Long-Term Impact on Falls in a French Nursing Home.

Pharmacy (Basel) 2018 Apr 6;6(2). Epub 2018 Apr 6.

Service Pharmacie, CHU de Strasbourg, Faculté de Pharmacie, EA7396, 67091 Strasbourg, France.

Long-term use of benzodiazepines (BZDs) is known to induce tolerance and dependence, and increase the risk of falls-related injuries in older adults. We present a study carried out in a French nursing home that concerns the implementation of a BZD withdrawal program reassessed at one year. BZD deprescription was achieved by gradual cessation of doses. A secondary benefit of this program was assessed by comparing the number of falls among residents before and after withdrawal. The number of falls was recorded over a six-month period prior to the onset of withdrawal (T1) and then over a six-month period after reassessment at one year (T2). At the beginning, 31 (28.7%) of the patients were under BZD. Total deprescription was obtained for 11 patients. The number of falls per patient over the T1 period was not different between the two groups (future non-withdrawn and withdrawn patients in BZD): 2.1 ± 1.3 and 2.3 ± 0.6 falls per resident, respectively. Conversely, the number of falls per patient was significantly decreased in the population completely withdrawn in BZD between the T1 and T2 periods (2.3 ± 0.6 vs. 0.5 ± 0.2 falls, = 0.01). The results show that BZD deprescription, through a gradual reduction of doses, is possible to achieve.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/pharmacy6020030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024993PMC
April 2018

[Increased QT interval due to antiandrogenic therapy, majorated by psychotropic drugs: About one case].

Therapie 2017 Dec 16;72(6):701-703. Epub 2017 Jul 16.

Établissement public de santé Alsace Nord, service de pharmacie, pharmacie clinique, 67170 Brumath, France. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.therap.2017.05.003DOI Listing
December 2017

Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.

MAbs 2017 Feb/Mar;9(2):383-390. Epub 2016 Dec 8.

e Laboratoire d'épidémiologie et de santé publique - EA3430, Faculté de Médecine, Université de Strasbourg , Strasbourg , France.

This study's aims were: 1) to extract a comprehensive overview of the knowledge, experience and opinions of both community pharmacists and hospital pharmacists regarding biosimilar medicines in France; and 2) to identify the perceived problems and solutions to promoting their prescription. A 2015 web-based survey was conducted by the Observatoire des Médicaments, des Dispositifs Médicaux et de l'Innovation Thérapeutique of Alsace. A total of 802 pharmacists responded to the survey. Many (536, 66.8%, [95% confidence interval (CI) 63.6-70.1]) indicated that they were not familiar with biosimilars. Half of community pharmacists (95% CI 42.7-57.3) stated that they were not at all informed about biosimilar drugs, compared with 15.7% (95% CI 12.9-18.6) of hospital pharmacists. Almost all respondents (781, 97.4%, [95% CI 96.3-98.5]) had at least one pending question on biosimilars. Most of the questions were related to the manufacturing process, safety, substitution rules and the international non-proprietary name prescription. At the time of the study, 467 pharmacists (58.2%, [95% CI 54.8-61.6]) had already validated a prescription for a biosimilar drug, mainly for filgrastim. These latter were more comfortable in explaining the benefit of biosimilar medicines to the patient. Pharmacists were rather favorable to biosimilar drugs, and about 9 of 10 quoted healthcare cost savings as incentives to their prescription. However, many did not agree with allowing biosimilar substitution. "Patients' wishes to be treated with the originator" and "indication extrapolation" were the two main constraints identified. The survey highlighted the need to provide French pharmacists with accurate and comprehensive information regarding biosimilar medicines.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2016.1267087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297517PMC
November 2017

Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.

BioDrugs 2016 Dec;30(6):585-592

Laboratoire d'épidémiologie et de santé publique-EA3430, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.

Background: Healthcare cost savings are closely linked to prescribers' confidence in and acceptance of the prescription of biosimilar drugs.

Objectives: The aim of this study was to assess the knowledge, experience and opinions of hospital-based and office-based French rheumatologists with regard to biosimilar medicines and to identify the barriers to and possible options to promote their prescription.

Methods: A web-based, self-administered survey was conducted among French rheumatologists from June 8 to August 2, 2015.

Results: A total of 116 rheumatologists responded to the survey. Many reported having little knowledge and a lack of available information about biosimilar drugs, especially office-based rheumatologists. 98.3% of the respondents had at least one question about biosimilars, and seven in ten raised issues regarding substitution, iatrogenic effects or cost savings that might be achievable. Only eight rheumatologists had already prescribed a biosimilar drug. The most common barriers reported were indication extrapolation and a lack of data about tolerability. Nine out of ten physicians thought that starting a treatment with a biosimilar drug in biologic treatment-naïve patients was possible. The rheumatologists' opinions were rather favorable towards the implementation of biosimilars, but a majority expressed a negative opinion about substitution by the pharmacist.

Conclusions: Our survey gave a better appreciation of the concerns associated with biosimilar prescriptions. Targeted communication initiatives, deeper experience and availability of new clinical data may help to address the outstanding questions and should overcome the misunderstandings surrounding biosimilar drugs among rheumatologists.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-016-0202-5DOI Listing
December 2016

A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution.

Case Rep Psychiatry 2016 12;2016:7031245. Epub 2016 Oct 12.

OMEDIT Alsace, Faculté de Pharmacie-Laboratoire HuManiS (EA 7308), Service Pharmacie-CHRU de Strasbourg, Strasbourg, France.

Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsidering the real risk of tardive dyskinesia associated with aripiprazole, particularly in the elderly.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/7031245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080510PMC
October 2016

A first higher-level time-calibrated phylogeny of antlions (Neuroptera: Myrmeleontidae).

Mol Phylogenet Evol 2017 02 22;107:103-116. Epub 2016 Oct 22.

CNRS, UMR 5554 Institut des Sciences de l'Evolution (Université de Montpellier), Place Eugène Bataillon, 34095 Montpellier, France. Electronic address:

In this study, we reconstruct the first time-calibrated phylogeny of the iconic antlion family, the Myrmeleontidae (Neuroptera: Myrmeleontiformia). We use maximum likelihood and Bayesian inference to analyse a molecular dataset based on seven mitochondrial and nuclear gene markers. The dataset encompasses 106 species of Neuroptera, including 94 antlion species. The resulting phylogenetic framework provides support for a myrmeleontid classification distinguishing four subfamilies: Acanthaclisinae, Myrmeleontinae, Palparinae, and Stilbopteryginae. Within Myrmeleontinae, Myrmecaelurini and Nemoleontini are recovered as monophyletic clades; Gepini also appears as a valid tribe, distinct from Myrmecaelurini whereas Myrmecaelurini and Nesoleontini on one hand and Brachynemurini and Dendroleontini on the other hand, appear closely related. Some preliminary information related to generic and specific levels are also implied from our results, such as the paraphyly of several genera. Dating analyses based on thoroughly evaluated fossil calibrations indicate that the antlion family likely originated in the Cretaceous, between 135 and 138 million years ago (depending on the set of fossil calibrations), and that all higher-level lineages appeared during the Early Cretaceous. This first phylogenetic hypothesis will provide a valuable basis to further expand the taxonomic coverage and molecular sampling, and to lay the foundations of future systematic revisions.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ympev.2016.10.014DOI Listing
February 2017

Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace.

Drugs Real World Outcomes 2015 Sep;2(3):205-215

OMEDIT Alsace, Agence Régionale de Santé d'Alsace, 14, rue du Maréchal Juin, 67084, Strasbourg Cedex, France.

Background: The economic burden linked to rheumatoid arthritis (RA) has greatly increased since the inclusion of biotherapies in the therapeutic arsenal.

Objectives: This study aimed first to look at the breakdown of the rheumatoid arthritis patients on biotherapy in Alsace, France, in 2012, then to evaluate the annual cost per treated patient for each management pathway: inpatient care with intravenous biotherapies and/or outpatient care through the use of subcutaneous drugs, and finally to conduct a cost comparison with a focus on infliximab, adalimumab and etanercept.

Methods: This observational study was conducted in Alsace using 2012 health claims data from the DCIR (Données de Consommation Inter Régime) and PMSI (Programme de Médicalisation des Systèmes d'Information) databases, taking into account direct medical and non-medical costs in a real-life setting and from a National Health Insurance perspective.

Results: There were 5702 RA patients, i.e. 0.31 % of the Alsace population in 2012, including 1075 subjects (18.85 %) receiving biotherapy treatment. The most frequently prescribed biotherapies were etanercept and adalimumab. The estimated overall cost of care of these 5702 patients was €30.3 million, with about 50 % for the care of the 18.85 % patients on biotherapy. Average costs for inpatient, outpatient and mixed care ranged from €14,197 to €16,873 per patient per year. Annual average cost for management of a single RA patient with infliximab was significantly higher than with adalimumab and etanercept: €16,480 versus €14,116 and €14,338, respectively.

Conclusion: These findings confirm the trends of initial modelling approaches and quantify the cost difference between various biotherapy management pathways.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40801-015-0030-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883212PMC
September 2015

Drug-dispensing problems community pharmacists face when patients are discharged from hospitals: a study about 537 prescriptions in Alsace.

Int J Qual Health Care 2016 Dec;28(6):779-784

OMEDIT Alsace, Agence Régionale de Santé d'Alsace, 67084 Strasbourg Cedex, France.

Objectives: To identify both type and frequency of the challenges community pharmacists face when dispensing drugs from hospital discharge prescriptions, to describe the measures undertaken to resolve the issues at stake and to list their consequences.

Design: We carried out an observational study in the community pharmacies of the French region of Alsace and asked the community pharmacy staff to review 537 hospital discharge prescriptions in 2013 using anonymous data collection forms.

Setting And Participants: Nineteen community pharmacies.

Main Outcome Measures: Number of patients informed about their medication (at hospital and/or community pharmacy), type and frequency of issues encountered during drug dispensing, type and frequency of measures undertaken to resolve the issues, type and frequency of the consequences regarding drug dispensing.

Results: Community pharmacists faced 165 challenges from 145 hospital discharge prescriptions (i.e. 27.5% out of 528 analysed prescriptions), mostly correlated to the quality of the prescriptions (n = 100, 60.6%) or to logistical matters (n = 54, 32.7%). A mere 36.8% of the patients received information pertaining to their medication while being hospitalized. Of note, 40.5% of the prescriptions were delivered to pharmacies within 2 days following the patients' discharge. In order to resolve the different issues preventing drugs from being dispensed (n = 33/145 prescriptions), pharmacists sought information, mainly from patients, colleagues and hospital prescribers. The pharmacists were able to dispense all the drugs prescribed in 138 out of 145 cases (95.2%).

Conclusions: This study highlighted the challenges encountered by community pharmacists and their significant contribution to the continuity of care upon patients being discharged from hospitals.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1093/intqhc/mzw111DOI Listing
December 2016

Clozapine-induced esophagitis at therapeutic dose: a case report.

Braz J Psychiatry 2016 Apr-Jun;38(2):177

Service G06, EPSAN, EPSAN, Brumath , France, Service G06, EPSAN, Brumath, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1590/1516-4446-2015-1787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111375PMC
December 2016

Acute withdrawal syndrome after discontinuation of a short analgesic treatment with tramadol.

Therapie 2016 Jun 17;71(3):347-8. Epub 2016 Mar 17.

Centre régional de pharmacovigilance de Lorraine, CHRU de Nancy, 54000 Nancy, France.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.therap.2015.11.007DOI Listing
June 2016